{"title":"Effects of estrogen, orchidectomy, and cyproterone acetate on tissue fibrinolysis in patients with carcinoma of the prostate.","authors":"E Varenhorst, B Risberg","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Twenty-six patients with carcinoma of the prostate were allocated to treatment by subcapsular orchidectomy, estrogen administration, or cyproterone acetate administration. Tissue fibrinolytic activity in skin biopsy specimens was estimated by a histochemical method before treatment was initiated and 2 and 8 weeks later. Orchidectomy caused no significant changes in the fibrinolytic activity. During estrogen therapy the fibrinolytic activity in skin was significantly reduced at 8 weeks. In the group given cyproterone acetate the activity was significantly increased at 8 weeks. In the group given cyproterone acetate the activity was significantly increased at 8 weeks. The reduction in fibrinolytic activity in skin could contribute to the increased risk of thromboembolism during estrogen treatment of patients with cancer of the prostate.</p>","PeriodicalId":14519,"journal":{"name":"Investigative urology","volume":"18 5","pages":"355-7"},"PeriodicalIF":0.0000,"publicationDate":"1981-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Investigative urology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Twenty-six patients with carcinoma of the prostate were allocated to treatment by subcapsular orchidectomy, estrogen administration, or cyproterone acetate administration. Tissue fibrinolytic activity in skin biopsy specimens was estimated by a histochemical method before treatment was initiated and 2 and 8 weeks later. Orchidectomy caused no significant changes in the fibrinolytic activity. During estrogen therapy the fibrinolytic activity in skin was significantly reduced at 8 weeks. In the group given cyproterone acetate the activity was significantly increased at 8 weeks. In the group given cyproterone acetate the activity was significantly increased at 8 weeks. The reduction in fibrinolytic activity in skin could contribute to the increased risk of thromboembolism during estrogen treatment of patients with cancer of the prostate.